Literature DB >> 2824604

Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.

M Caligiuri1, C Murray, D Buchwald, H Levine, P Cheney, D Peterson, A L Komaroff, J Ritz.   

Abstract

Natural killer (NK)3 cells are large granular lymphocytes that appear to play a significant role in the host's defense against viral infection. We performed an extensive phenotypic and functional characterization of NK cells on 41 patients with the chronic fatigue syndrome (CFS), or "chronic active Epstein-Barr virus infection" syndrome, and on 23 age- and sex-matched asymptomatic control subjects in an attempt to further characterize this illness. These studies demonstrated that a majority of patients with CFS have low numbers of NKH1+T3- lymphocytes, a population that represents the great majority of NK cells in normal individuals. CFS patients had normal numbers of NKH1+T3+ lymphocytes, a population that represents a relatively small fraction of NK cells in normal individuals. When tested for cytotoxicity against a variety of different target cells, patients with CFS consistently demonstrated low levels of killing. After activation of cytolytic activity with recombinant interleukin 2, patients were able to display increased killing against K562 but most patients remained unable to lyse Epstein-Barr virus-infected B cell targets. Additional cytotoxicity experiments were carried out utilizing anti-T3 monoclonal antibody to block killing by NKH1+T3+ cells. These experiments indicated that the NK cell that appears to be responsible for much of the functional activity remaining in patients with CFS belongs to the NKH1+T3+ subset, which under normal circumstances represents only approximately 20% of the NK cell population.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824604

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Chronic fatigue syndrome: probable pathogenesis and possible treatments.

Authors:  Birgitta Evengård; Nancy Klimas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  The chronic fatigue syndrome: a return to common sense.

Authors:  A M Denman
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

3.  Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults.

Authors:  Cindy M Chang; Joan L Warren; Eric A Engels
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

4.  Chronic fatigue syndrome is associated with diminished intracellular perforin.

Authors:  K J Maher; N G Klimas; M A Fletcher
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

5.  Biological responses to overload training in endurance sports.

Authors:  R W Fry; A R Morton; P Garcia-Webb; G P Crawford; D Keast
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992

6.  The relationship between the frequency of the common cold and the activities of natural killer cells.

Authors:  M Xu; T Muto; T Yabe; F Nagao; Y Fukuwatart; K Okumura
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

7.  Heterogeneity of human natural killer cells in the spleen.

Authors:  T Witte; K Wordelmann; R E Schmidt
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

8.  Immunologic abnormalities in chronic fatigue syndrome.

Authors:  N G Klimas; F R Salvato; R Morgan; M A Fletcher
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

9.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

10.  Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.

Authors:  Kenny L De Meirleir; Svetlana F Khaiboullina; Marc Frémont; Jan Hulstaert; Albert A Rizvanov; András Palotás; Vincent C Lombardi
Journal:  In Vivo       Date:  2013 Mar-Apr       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.